Ex vivo dual gene therapy using human adipocytes secreting anti-HER2 antibody on HER2-positive xenograft tumor models-Reference-Cited by-同舟云学术

Ex vivo dual gene therapy using human adipocytes secreting anti-HER2 antibody on HER2-positive xenograft tumor models

Published:2023-08-23 Issue:6 Volume:30 Page:1018-1027
ISSN:1340-6868
Container-title:Breast Cancer
language:en
Short-container-title:Breast Cancer

Author:

Teranaka Ryotaro,Fujimoto Hiroshi^ORCID,Masuda Takahito,Kuroda Masayuki,Aoyagi Yasuyuki,Nagashima Takeshi,Takada Mamoru,Sakakibara Junta,Yamada Hideyuki,Yamamoto Hiroto,Kubota Yoshitaka,Ohtsuka Masayuki

Funder

MEXT KAKENHI

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12282-023-01497-8.pdf

Reference33 articles.

1. Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432–44.

2. Anan K, Mitsuyama S, Koga K, Tanabe R, Saimura M, Tanabe Y, et al. Disparities in the survival improvement of recurrent breast cancer. Breast Cancer. 2010;17(1):48–55.

3. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving? Cancer. 2004;100(1):44–52.

4. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al. Herceptin adjuvant trial study T, 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial. Lancet. 2017;389(10075):1195–205.

5. Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol. 2014;15(6):640–7.